ARK Genomic Revolution ETF vs Byrna Technologies Inc — how do they compare? ARK Genomic Revolution ETF trades at $44.49, while Byrna Technologies Inc trades at $4.32 (market cap $106.74M). The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, Byrna Technologies Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | BYRN | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $44.55 | $27.63 |
52-Week Low | $24.02 | $3.18 |
Market Cap | — | $106.74M |
Enterprise Value | — | $98.35M |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
BYRN trades at $4.32, down 10.93% amid weak Q2 2026 results, with revenue declining 42.5% and a significant EPS miss. The stock shows a bullish technical signal from moving averages but faces fundamental headwinds with negative net income and ROE. Recent management changes and marketing initiatives aim to address sales challenges, while an ongoing legal investigation adds uncertainty.
The outlook is mixed; analyst consensus is 71% buy with potential from new leadership and product expansion, but execution risk is high given profit declines and competitive pressures. Investors should weigh turnaround efforts against persistent operational weaknesses and legal overhangs for near-term volatility.
Trailing returns across standard periods
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →Byrna Technologies specializes in less-lethal personal security devices. It develops and manufactures innovative handheld launchers and projectiles designed for self-defense, law enforcement, and private security use.
Read more on BYRN →